Zeltiq Aesthetics Inc 4
4 · Zeltiq Aesthetics Inc · Filed Apr 28, 2017
Insider Transaction Report
Form 4
Harris Taylor C.
SVP & Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2017-04-28−22,232→ 0 totalExercise: $40.89Exp: 2027-01-17→ Common Stock (22,232 underlying) - Disposition to Issuer
Common Stock
2017-04-28−62,705→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2017-04-28−106,411→ 0 totalExercise: $20.81Exp: 2026-02-01→ Common Stock (106,411 underlying)
Footnotes (2)
- [F1]Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 62,705 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
- [F2]In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares underlying this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.